Enterprise Value
19.9M
Cash
10.01M
Avg Qtr Burn
-8.436M
Short % of Float
7.71%
Insider Ownership
5.91%
Institutional Own.
7.70%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vyleesi® (bremelanotide) MC4r Agonist Details Sexual dysfunction, Sexual desire disorder, Influenza | Approved Quarterly sales | |
PL9643 Details Eye disease , Dry eye syndrome | Phase 3 Update | |
Bremelanotide + GLP-1 Details Obesity, Metabolic disorder | Phase 2 Data readout | |
PL8177 Details Chronic inflammatory disorder, Inflammatory disease, Bowel disorder, Ulcerative colitis | Phase 2 Data readout | |
Bremelanotide + PDE5i Details Erectile dysfunction
| Phase 2 Data readout | |
Bremelanotide Details Diabetic Kidney Disease | Phase 2 Data readout | |
Failed Discontinued | ||
PL8177 Details Eye disease , Inflammatory disease | Failed Discontinued | |
PL3994 (NPR-A agonist) Details Heart disease | Failed Discontinued |